Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,400.11 | 21.03 | -0.25% |
| DAX 40 | 25,139.69 | 153.87 | 0.62% |
| Dow JONES (US) | 51,712.71 | 148.01 | 0.29% |
| FTSE 100 | 10,437.85 | 74.58 | 0.72% |
| HKSE | 23,265.24 | 503.28 | -2.12% |
| NASDAQ | 26,166.60 | 351.33 | -1.32% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,472.79 | 27.79 | -0.37% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.84 | 56.26 | -1.35% |